Cognition Therapeutics Inc., a Pittsburgh, PA-based pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, completed a $12m Series B financing.
The round was led by Golden Seeds with participation from Bios Memory SPV1, Cowtown Angels, Scale Investors, Dolby Family Ventures, Maine Angels, as well as additional life sciences investors, and existing investors Ogden CAP, PLSG Accelerator Fund, Tech Coast Angels, ACE Fund, Ariel Southeast Angel Partners and M5Invest Partners.
The company is using the funds to advance its lead Alzheimer’s program into Phase 1 clinical studies by the end of 2015.
Led by Dr. Hank Safferstein, Chief Executive Officer, Cognition Therapeutics is a pharmaceutical company using disease-relevant screening and novel chemistry platform approaches to produce a pipeline of new small molecule drug candidates for protein misfolding diseases of the nervous system. Its leading clinical candidate-stage program is a highly brain-penetrant, orally bioavailable small molecule receptor antagonist that blocks memory deficits in Alzheimer’s disease models.